Cargando…

Update on Denosumab Treatment in Postmenopausal Women with Osteoporosis

Denosumab, a fully human recombinant monoclonal antibody to the receptor activator of nuclear factor-κB ligand (RANKL), blocks binding of RANKL to the RANK receptor, found on the surface of osteoclasts and osteoclast precursors, resulting in decreased bone resorption. Subcutaneous denosumab administ...

Descripción completa

Detalles Bibliográficos
Autor principal: Min, Yong-Ki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Endocrine Society 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4384669/
https://www.ncbi.nlm.nih.gov/pubmed/25827453
http://dx.doi.org/10.3803/EnM.2015.30.1.19
_version_ 1782364939621498880
author Min, Yong-Ki
author_facet Min, Yong-Ki
author_sort Min, Yong-Ki
collection PubMed
description Denosumab, a fully human recombinant monoclonal antibody to the receptor activator of nuclear factor-κB ligand (RANKL), blocks binding of RANKL to the RANK receptor, found on the surface of osteoclasts and osteoclast precursors, resulting in decreased bone resorption. Subcutaneous denosumab administration once every 6 months increases bone mineral density at the lumbar spine, total hip, and/or femoral neck, and reduces markers of bone turnover significantly in postmenopausal women with osteoporosis. Relative to placebo, denosumab treatment reduces the risk of vertebral, nonvertebral, and hip fractures significantly. The benefits of denosumab treatment are generally obvious after the first dose and were continued for up to 8 years of treatment in an extension study. The tolerability profile of denosumab during this extension phase was consistent with that observed during the initial 3-year FREEDOM trial. Postmarketing safety surveillance has not shown any unexpected findings. Ongoing safety surveillance will more fully define the long-term safety of denosumab. The benefits of denosumab would seem to be greater than its risks. Denosumab is an important choice in the treatment of postmenopausal women with osteoporosis at increased risk of fractures, including older patients who have difficulty with oral bisphosphonate intake and patients who are intolerant of, or unresponsive to, other therapies.
format Online
Article
Text
id pubmed-4384669
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Korean Endocrine Society
record_format MEDLINE/PubMed
spelling pubmed-43846692015-04-07 Update on Denosumab Treatment in Postmenopausal Women with Osteoporosis Min, Yong-Ki Endocrinol Metab (Seoul) Review Article Denosumab, a fully human recombinant monoclonal antibody to the receptor activator of nuclear factor-κB ligand (RANKL), blocks binding of RANKL to the RANK receptor, found on the surface of osteoclasts and osteoclast precursors, resulting in decreased bone resorption. Subcutaneous denosumab administration once every 6 months increases bone mineral density at the lumbar spine, total hip, and/or femoral neck, and reduces markers of bone turnover significantly in postmenopausal women with osteoporosis. Relative to placebo, denosumab treatment reduces the risk of vertebral, nonvertebral, and hip fractures significantly. The benefits of denosumab treatment are generally obvious after the first dose and were continued for up to 8 years of treatment in an extension study. The tolerability profile of denosumab during this extension phase was consistent with that observed during the initial 3-year FREEDOM trial. Postmarketing safety surveillance has not shown any unexpected findings. Ongoing safety surveillance will more fully define the long-term safety of denosumab. The benefits of denosumab would seem to be greater than its risks. Denosumab is an important choice in the treatment of postmenopausal women with osteoporosis at increased risk of fractures, including older patients who have difficulty with oral bisphosphonate intake and patients who are intolerant of, or unresponsive to, other therapies. Korean Endocrine Society 2015-03 2015-03-27 /pmc/articles/PMC4384669/ /pubmed/25827453 http://dx.doi.org/10.3803/EnM.2015.30.1.19 Text en Copyright © 2015 Korean Endocrine Society http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Min, Yong-Ki
Update on Denosumab Treatment in Postmenopausal Women with Osteoporosis
title Update on Denosumab Treatment in Postmenopausal Women with Osteoporosis
title_full Update on Denosumab Treatment in Postmenopausal Women with Osteoporosis
title_fullStr Update on Denosumab Treatment in Postmenopausal Women with Osteoporosis
title_full_unstemmed Update on Denosumab Treatment in Postmenopausal Women with Osteoporosis
title_short Update on Denosumab Treatment in Postmenopausal Women with Osteoporosis
title_sort update on denosumab treatment in postmenopausal women with osteoporosis
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4384669/
https://www.ncbi.nlm.nih.gov/pubmed/25827453
http://dx.doi.org/10.3803/EnM.2015.30.1.19
work_keys_str_mv AT minyongki updateondenosumabtreatmentinpostmenopausalwomenwithosteoporosis